Effects of prophylactic indomethacin on morbidity and mortality in infants <25 weeks' gestation: a protocol driven intention to treat analysis.
Effects of prophylactic indomethacin on morbidity and mortality in infants <25 weeks' gestation: a protocol driven intention to treat analysis.
复制标题
DOI：
10.1038/s41372-022-01547-7
复制
发表时间：
2022-12
影响因子：
2.9
通讯作者：
Hills, Nancy K.
中科院分区：
文献类型：
--
作者：
Clyman, Ronald, I;Hills, Nancy K.
确定预防性吲哚美辛（PINDO）是否可减少25周以下新生儿的死亡或支气管肺发育不良-2级和3级（死亡/BPD）。对106名在PINDO或预期动脉导管未闭（PDA）治疗的三个交替时期住院的婴儿进行的意向治疗、队列对照研究。在第7-8天，85%的期待治疗期婴儿患有中度/重度PDA（中位暴露时间为23天）。在PINDO时期的婴儿中，只有24%在7-8天时仍然有PDA。在PINDO时期出生的婴儿和期待治疗时期出生的婴儿之间，在未校正或校正的比较中，死亡/BPD或次要结局（BPD、死亡、坏死性小肠结肠炎/自发性穿孔或脑室内出血（3级或4级））的发生率无显著差异。尽管PINDO具有PDA相关疾病的高风险，但PINDO似乎并未改变25周以下婴儿的主要和次要结局。
To determine if prophylactic indomethacin (PINDO) decreases death or bronchopulmonary dysplasia-grades 2 and 3 (death/BPD) in newborns <25 weeks. Intention-to-treat, cohort-controlled study of 106 infants admitted during three alternating epochs of PINDO or Expectant patent ductus arteriosus (PDA) management. At 7–8 days 85% of Expectant Management epoch infants had a moderate/large PDA (median exposure was 23 days). Among PINDO epoch infants only 24% still had a PDA at 7–8 days. There were no significant differences in the incidence of death/BPD or of secondary outcomes (BPD, death, necrotizing enterocolitis/spontaneous perforations, or intraventricular hemorrhage (grades 3 or 4)) in either unadjusted or adjusted comparisons between infants born in a PINDO epoch and those born in the Expectant Management epoch. Despite being at high risk for PDA-related morbidities, PINDO did not appear to alter the rates of our primary and secondary outcomes in infants <25 weeks.
登录
查看更多内容
影响因子：
2.5
作者：
Hundscheid T;Donders R;Onland W;Kooi EMW;Vijlbrief DC;de Vries WB;Nuytemans DHGM;van Overmeire B;Mulder AL;de Boode WP;BeNeDuctus trial study group
通讯作者：
BeNeDuctus trial study group
影响因子：
2.5
作者：
Bell JL;Gupta S;Juszczak E;Hardy P;Linsell L
通讯作者：
Linsell L
PDA-验证试验：一项探索性随机对照试验，是对1周大的中度至大型专利导管的治疗。
DOI：
10.1016/j.jpeds.2018.09.012
发表时间：
2019-03
期刊：
The Journal of pediatrics
影响因子：
--
作者：
Clyman RI;Liebowitz M;Kaempf J;Erdeve O;Bulbul A;Håkansson S;Lindqvist J;Farooqi A;Katheria A;Sauberan J;Singh J;Nelson K;Wickremasinghe A;Dong L;Hassinger DC;Aucott SW;Hayashi M;Heuchan AM;Carey WA;Derrick M;Fernandez E;Sankar M;Leone T;Perez J;Serize A;PDA-TOLERATE (PDA: TO LEave it alone or Respond And Treat Early) Trial Investigators
通讯作者：
PDA-TOLERATE (PDA: TO LEave it alone or Respond And Treat Early) Trial Investigators
影响因子：
2.4
作者：
Fenton TR;Kim JH
通讯作者：
Kim JH
影响因子：
5.1
作者：
Hagadorn, James, I;Bennett, Mihoko, V;Lee, Henry C.
通讯作者：
Lee, Henry C.